

Refine Search

Search Results -

Terms	Documents
(staurosporin and L12)	18

Database:

US Pre-Grant Publication Full-Text Database

US Patents Full-Text Database

US OCR Full-Text Database

EPO Abstracts Database

JPO Abstracts Database

Derwent World Patents Index

IBM Technical Disclosure Bulletins

Search:

L13

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Wednesday, March 08, 2006 [Printable Copy](#) [Create Case](#)

Set Name Query

side by side

DB=PGPB; PLUR=YES; OP=OR

<u>L13</u>	(staurosporin and l12)
<u>L12</u>	L11 and (inhibit protein synthesis)
<u>L11</u>	L10 and (sustained release dosage form)
<u>L10</u>	L9 and (reduce restenosis)
<u>L9</u>	L8 and (non-biodegradable)
<u>L8</u>	L7 and kinase inhibitor
<u>L7</u>	suramin and (vascular smooth muscle cell migration inhibition)
<u>L6</u>	L1 and (inhibit protein synthesis)
<u>L5</u>	L1 and (cytotoxicity)
<u>L4</u>	l1 and (free therapeutic agent)
<u>L3</u>	l1 and free therapeutic agent
<u>L2</u>	L1 and non-biodegradable
<u>L1</u>	20020013275

Hit Count Set Name

result set

18	<u>L13</u>
867	<u>L12</u>
892	<u>L11</u>
894	<u>L10</u>
1058	<u>L9</u>
82604	<u>L8</u>
1493	<u>L7</u>
1	<u>L6</u>
1	<u>L5</u>
1	<u>L4</u>
267819	<u>L3</u>
1	<u>L2</u>
1	<u>L1</u>

END OF SEARCH HISTORY

Hit List

[Clear](#) [Generate Collection](#) [Print](#) [Fwd Refs](#) [Bkwd Refs](#) [Generate OACS](#)

Search Results - Record(s) 1 through 10 of 18 returned.

☐ 1. Document ID: US 20060004437 A1

L13: Entry 1 of 18

File: PGPB

Jan 5, 2006

PGPUB-DOCUMENT-NUMBER: 20060004437

PGPUB-FILING-TYPE:

DOCUMENT-IDENTIFIER: US 20060004437 A1

TITLE: Structurally variable stents

PUBLICATION-DATE: January 5, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Jayaraman; Swaminathan	Fremont	CA	US

US-CL-CURRENT: 623/1.16; 623/1.42

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MOE	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-----

☐ 2. Document ID: US 20050158333 A1

L13: Entry 2 of 18

File: PGPB

Jul 21, 2005

PGPUB-DOCUMENT-NUMBER: 20050158333

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050158333 A1

TITLE: Methods and products related to metabolic interactions in disease

PUBLICATION-DATE: July 21, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Newell, Martha Karen	Colorado Springs	CO	US

US-CL-CURRENT: 424/185.1; 514/12

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MOE	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-----

☐ 3. Document ID: US 20050074882 A1

L13: Entry 3 of 18

File: PGPB

Apr 7, 2005

PGPUB-DOCUMENT-NUMBER: 20050074882

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050074882 A1

TITLE: Methods and products related to metabolic interactions in disease

PUBLICATION-DATE: April 7, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Newell, Martha Karen	Colorado Springs	CO	US

US-CL-CURRENT: 435/455; 424/85.5, 514/34, 514/558

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-----

☐ 4. Document ID: US 20050054563 A1

L13: Entry 4 of 18

File: PGPB

Mar 10, 2005

PGPUB-DOCUMENT-NUMBER: 20050054563

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050054563 A1

TITLE: Methods of treatment using wisp polypeptides

PUBLICATION-DATE: March 10, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Desnoyer, Luc	San Francisco	CA	US
Filvaroff, Ellen H.	San Francisco	CA	US
Pennica, Diane	Burlingame	CA	US

US-CL-CURRENT: 514/12

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-----

☐ 5. Document ID: US 20050042224 A1

L13: Entry 5 of 18

File: PGPB

Feb 24, 2005

PGPUB-DOCUMENT-NUMBER: 20050042224

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050042224 A1

TITLE: Methods and products related to metabolic interactions in disease

PUBLICATION-DATE: February 24, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Newell, Martha Karen	Colorado Springs	CO	US

US-CL-CURRENT: 424/155.1; 514/251, 514/34

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-----

☐ 6. Document ID: US 20040243214 A1

L13: Entry 6 of 18

File: PGPB

Dec 2, 2004

PGPUB-DOCUMENT-NUMBER: 20040243214
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040243214 A1

TITLE: Coated stent with protective packaging and method of using same

PUBLICATION-DATE: December 2, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Farrell, Thomas	Galway		IE
Quinn, Colm	Longford		IE

US-CL-CURRENT: 623/1.11; 206/370, 623/1.46

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMK	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-----

☐ 7. Document ID: US 20040219223 A1

L13: Entry 7 of 18

File: PGPB

Nov 4, 2004

PGPUB-DOCUMENT-NUMBER: 20040219223
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040219223 A1

TITLE: Therapeutic inhibitor of vascular smooth muscle cells

PUBLICATION-DATE: November 4, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Kunz, Lawrence L.	Redmond	WA	US

US-CL-CURRENT: 424/489; 623/1.42

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMK	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-----

☐ 8. Document ID: US 20040181277 A1

L13: Entry 8 of 18

File: PGPB

Sep 16, 2004

PGPUB-DOCUMENT-NUMBER: 20040181277
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040181277 A1

TITLE: Irradiated stent coating

PUBLICATION-DATE: September 16, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Furst, Joseph G.	Middlefield	OH	US

US-CL-CURRENT: 623/1.16

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMK	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-----

☐ 9. Document ID: US 20030203958 A1

L13: Entry 9 of 18

File: PGPB

Oct 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030203958

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030203958 A1

TITLE: Therapeutic inhibitor of vascular smooth muscle cells

PUBLICATION-DATE: October 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Kunz, Lawrence L.	Redmond	WA	US
Klein, Richard A.	Edmonds	WA	US
Reno, John M.	Brier	WA	US

US-CL-CURRENT: 514/411; 514/449

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-----

☐ 10. Document ID: US 20030187493 A1

L13: Entry 10 of 18

File: PGPB

Oct 2, 2003

PGPUB-DOCUMENT-NUMBER: 20030187493

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030187493 A1

TITLE: Coated stent with protective assembly and method of using same

PUBLICATION-DATE: October 2, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Campbell, Todd	Petaluma	CA	US
Cervantes, Marvin	Santa Rosa	CA	US

US-CL-CURRENT: 623/1.11; 623/1.42

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-----

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Terms

Documents

(staurosporin and L12)

18

Display Format: CIT

Change Format

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[Clear](#) [Generate Collection](#) [Print](#) [Fwd Refs](#) [Bkwd Refs](#) [Generate OACS](#)

Search Results - Record(s) 11 through 18 of 18 returned.

☐ 11. Document ID: US 20030083733 A1

L13: Entry 11 of 18

File: PGPB

May 1, 2003

PGPUB-DOCUMENT-NUMBER: 20030083733

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030083733 A1

TITLE: Therapeutic inhibitor of vascular smooth muscle cells

PUBLICATION-DATE: May 1, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Kunz, Lawrence L.	Redmond	WA	US

US-CL-CURRENT: 623/1.15; 424/423, 604/518, 623/1.42

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-----

☐ 12. Document ID: US 20030040790 A1

L13: Entry 12 of 18

File: PGPB

Feb 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030040790

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030040790 A1

TITLE: Stent coating

PUBLICATION-DATE: February 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Furst, Joseph G.	Middlefield	OH	US

US-CL-CURRENT: 623/1.11

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-----

☐ 13. Document ID: US 20030039675 A1

L13: Entry 13 of 18

File: PGPB

Feb 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030039675

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030039675 A1

TITLE: Therapeutic inhibitor of vascular smooth muscle cells

PUBLICATION-DATE: February 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Kunz, Lawrence L.	Redmond	WA	US
Reno, John M.	Brier	WA	US

US-CL-CURRENT: 424/423; 514/449, 514/720

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	NMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-----

☐ 14. Document ID: US 20020099438 A1

L13: Entry 14 of 18

File: PGPB

Jul 25, 2002

PGPUB-DOCUMENT-NUMBER: 20020099438

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020099438 A1

TITLE: Irradiated stent coating

PUBLICATION-DATE: July 25, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Furst, Joseph G.	Middlefield	OH	US

US-CL-CURRENT: 623/1.16

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	NMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-----

☐ 15. Document ID: US 20020086896 A1

L13: Entry 15 of 18

File: PGPB

Jul 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020086896

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020086896 A1

TITLE: Therapeutic inhibitor of vascular smooth muscle cells

PUBLICATION-DATE: July 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Kunz, Lawrence L.	Redmond	WA	US
Klein, Richard A.	Edmonds	WA	US
Reno, John M.	Brier	WA	US

US-CL-CURRENT: 514/449; 514/411

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	NMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-----

☐ 16. Document ID: US 20020040064 A1

L13: Entry 16 of 18

File: PGPB

Apr 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020040064
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020040064 A1

TITLE: Therapeutic inhibitor of vascular smooth muscle cells

PUBLICATION-DATE: April 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Kunz, Lawrence L.	Redmond	WA	US
Klein, Richard A.	Lynnwood	WA	US

US-CL-CURRENT: 514/656

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-----

☐ 17. Document ID: US 20020025979 A1

L13: Entry 17 of 18

File: PGPB

Feb 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020025979
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020025979 A1

TITLE: Therapeutic inhibitor of vascular smooth muscle cells

PUBLICATION-DATE: February 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Kunz, Lawrence L.	Redmond	WA	US
Reno, John M.	Brier	WA	US

US-CL-CURRENT: 514/411

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-----

☐ 18. Document ID: US 20020013275 A1

L13: Entry 18 of 18

File: PGPB

Jan 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020013275
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020013275 A1

TITLE: Therapeutic inhibitor of vascular smooth muscle cells

PUBLICATION-DATE: January 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Kunz, Lawrence L.	Redmond	WA	US
Klein, Richard A.	Lynnwood	WA	US
Reno, John M.	Brier	WA	US

Grainger, David J.	Cambridge	AL	GB
Metcalfe, James C.	Cambridge		GB
Weissberg, Peter L.	Cambridge		GB
Anderson, Peter G.	Birmingham		US

US-CL-CURRENT: 514/12; 514/2, 514/411

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-----

Clear	Generate Collection	Print	Fwd Refs	Blwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
(staurosporin and L12)	18

Display Format:

[Previous Page](#) [Next Page](#) [Go to Doc#](#)

Refine Search

Search Results -

Terms	Documents
6663881.pn.	1

Database:

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L10

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Wednesday, March 08, 2006 [Printable Copy](#) [Create Case](#)

Set Name Query Hit Count Set Name
side by side result set

DB=USPT; PLUR=YES; OP=OR

<u>L10</u>	6663881.pn.	1	<u>L10</u>
<u>L9</u>	6569441.pn.	1	<u>L9</u>
<u>L8</u>	6491938.pn.	1	<u>L8</u>
<u>L7</u>	6358989.pn.	1	<u>L7</u>
<u>L6</u>	6306421.pn.	1	<u>L6</u>
<u>L5</u>	5981568.pn.	1	<u>L5</u>
<u>L4</u>	5733925.pn.	1	<u>L4</u>
<u>L3</u>	5811447.pn.	1	<u>L3</u>
<u>L2</u>	6074659.pn.	1	<u>L2</u>
<u>L1</u>	6268390.pn.	1	<u>L1</u>

END OF SEARCH HISTORY

Continuity Information for 09/910388

Parent Data

09910388

is a continuation of 09470662

Which is a continuation of 09113733

Which is a continuation of 08450793

Which is a continuation of 08062451

Which is a continuation in part of 08011669

Which is a continuation in part of PCT/US92/08220 International Filing Date: 09/25/1992

Child Data

No Child Data

Appln Info	Contents	Petition Info	Atty/Agent Info	Continuity Data	Foreign Data	Inventors
------------	----------	---------------	-----------------	-----------------	--------------	-----------

Search Another: Application# Searchor Patent# SearchPCT / / Searchor PG PUBS # SearchAttorney Docket # SearchBar Code # Search

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

573 3 925

5 9 81568

6 3 06421

635 8 989

649 1 938

656 9441

666 3881

07767254 ABN

Pa. el. Filed 1 form 8 Jan 06

Continuity Information for 08/450793

Parent Data

08450793

is a continuation of 08062451

Which is a continuation in part of PCT/US92/08220 International Filing Date: 09/25/1992

Child Data

08738733 is a division of 08450793

08829685 is a continuation in part of 08450793

08829991 is a continuation in part of 08450793

09113733 is a continuation in part of 07767254

09361194 is a continuation in part of 08450793

09470662 is a continuation of 09113733

09896208 is a division of 08829991

09910388 is a continuation of 09470662

09995490 is a continuation of 09896208

10024885 is a continuation of 09361194

[Appin Info](#)[Contents](#)[Petition Info](#)[Atty/Agent Info](#)[Continuity
Data](#)[Foreign Data](#)[Inventors](#)

Search Another: Application#

or Patent#

PCT /

/




or PG PUBS #

Attorney Docket #

Bar Code #

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

Search PubMed for (vascular smooth muscle cell inhibition) and taxol   

Limits Preview/Index History Clipboard Details

Display Summary Show 20 Sort by Send to

About Entrez
NCBI ToolBar

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorials
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI


Related Resources
Order Documents
NLM Mobile
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Items 1 - 14 of 14


One page.

 1: Wu X, Huang L, Zhou Q, Song Y, Li A, Wang H, Song M.


[Related Articles](#), [Links](#)

 Effect of paclitaxel and mesenchymal stem cells seeding on ex vivo vascular endothelial repair and smooth muscle cells growth.


J Cardiovasc Pharmacol. 2005 Dec;46(6):779-86.
PMID: 16306802 [PubMed - indexed for MEDLINE]

 2: Kim SJ, Masaki T, Leyboldt JK, Kamerath CD, Mohammad SF, Cheung AK.


[Related Articles](#), [Links](#)

 Arterial and venous smooth-muscle cells differ in their responses to antiproliferative drugs.


J Lab Clin Med. 2004 Sep;144(3):156-62.
PMID: 15454885 [PubMed - indexed for MEDLINE]

 3: Sindermann JR, Verin V, Hopewell JW, Rodemann HP, Hendry JH.


[Related Articles](#), [Links](#)

 Biological aspects of radiation and drug-eluting stents for the prevention of restenosis.


Cardiovasc Res. 2004 Jul 1;63(1):22-30. Review.
PMID: 15194458 [PubMed - indexed for MEDLINE]

 4: Wang L, MacDonald RC.


[Related Articles](#), [Links](#)

 Effects of microtubule-depolymerizing agents on the transfection of cultured vascular smooth muscle cells: enhanced expression with free drug and especially with drug-gene lipoplexes.


Mol Ther. 2004 May;9(5):729-37.
PMID: 15120334 [PubMed - indexed for MEDLINE]

 5: Zheng XL, Gui Y, Du G, Frohman MA, Peng DQ.


[Related Articles](#), [Links](#)

 Calphostin-C induction of vascular smooth muscle cell apoptosis proceeds through phospholipase D and microtubule inhibition.


J Biol Chem. 2004 Feb 20;279(8):7112-8. Epub 2003 Dec 6.
PMID: 14660552 [PubMed - indexed for MEDLINE]

 6: Scheller B, Speck U, Romeike B, Schmitt A, Sovak M, Bohm M, Stoll HP.


[Related Articles](#), [Links](#)

 Contrast media as carriers for local drug delivery. Successful inhibition of neointimal proliferation in the porcine coronary stent model.


Eur Heart J. 2003 Aug;24(15):1462-7.
PMID: 12909076 [PubMed - indexed for MEDLINE]

 7: Sindermann JR, Skaletz-Rorowski A, Bartels A, Hohage H, Plenz G, Schmidt A, Breithardt G.

[Related Articles](#), [Links](#)


 Paclitaxel and cyclosporine A show supra-additive antiproliferative effects on smooth muscle cells by activation of protein kinase C.


Basic Res Cardiol. 2002 Mar;97(2):125-31.
PMID: 12002259 [PubMed - indexed for MEDLINE]


 8: Oberhoff M, Kunert W, Herdeg C, Kuttner A, Kranzhofer A, Horch B, Baumbach A, Karsch KR.

[Related Articles](#), [Links](#)


Inhibition of smooth muscle cell proliferation after local drug delivery of the

 **antimitotic drug paclitaxel using a porous balloon catheter.**
Basic Res Cardiol. 2001 May-Jun;96(3):275-82.
PMID: 11403421 [PubMed - indexed for MEDLINE]


 **9:** Heldman AW, Cheng L, Jenkins GM, Heller PF, Kim DW, Ware M Jr, Nater C, Hruban RH, Rezai B, Abella BS, Bunge KE, Kinsella JL, Sollott SJ, Lakatta EG, Brinker JA, Hunter WL, Froehlich JP. [Related Articles, Links](#)

 **Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis.**
Circulation. 2001 May 8;103(18):2289-95.
PMID: 11342479 [PubMed - indexed for MEDLINE]


 **10:** Nakamura M, Sunagawa M, Kosugi T, Sperelakis N. [Related Articles, Links](#)


 **Actin filament disruption inhibits L-type Ca(2+) channel current in cultured vascular smooth muscle cells.**
Am J Physiol Cell Physiol. 2000 Aug;279(2):C480-7.
PMID: 10913014 [PubMed - indexed for MEDLINE]


 **11:** Suh H, Jeong B, Rath R, Kim SW. [Related Articles, Links](#)


 **Regulation of smooth muscle cell proliferation using paclitaxel-loaded poly (ethylene oxide)-poly(lactide/glycolide) nanospheres.**
J Biomed Mater Res. 1998 Nov;42(2):331-8.
PMID: 9773830 [PubMed - indexed for MEDLINE]


 **12:** Leite R, Webb RC. [Related Articles, Links](#)

 **Microtubule disruption potentiates phenylephrine-induced vasoconstriction in rat mesenteric arterial bed.**
Eur J Pharmacol. 1998 Jun 12;351(1):R1-3.
PMID: 9698197 [PubMed - indexed for MEDLINE]

 **13:** Axel DL, Kunert W, Goggelmann C, Oberhoff M, Herdeg C, Kutner A, Wild DH, Brehm BR, Riessen R, Koveker G, Karsch KR. [Related Articles, Links](#)

 **Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery.**
Circulation. 1997 Jul 15;96(2):636-45.
PMID: 9244237 [PubMed - indexed for MEDLINE]

 **14:** Smith CD, Zhang X, Mooberry SL, Patterson GM, Moore RE. [Related Articles, Links](#)

 **Cryptophycin: a new antimicrotubule agent active against drug-resistant cells.**
Cancer Res. 1994 Jul 15;54(14):3779-84.
PMID: 7913408 [PubMed - indexed for MEDLINE]

Display Show Sort by Send to

[Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)
[Department of Health & Human Services](#)
[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Mar 6 2006 04:31:02

Refine Search

Search Results -

Terms	Documents
L1 and (does not inhibit protein synthesis)	1

Database:

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L4

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Wednesday, March 08, 2006 [Printable Copy](#) [Create Case](#)

Set Name Query

side by side

Hit Count Set Name

result set

DB=USPT; PLUR=YES; OP=OR

<u>L4</u>	L1 and (does not inhibit protein synthesis)	1	<u>L4</u>
<u>L3</u>	L1 and (does not exhibit cytotoxicity)	1	<u>L3</u>
<u>L2</u>	L1 and (sustained release dosage form)	1	<u>L2</u>
<u>L1</u>	5981568.pn.	1	<u>L1</u>

END OF SEARCH HISTORY

Search PubMed for reduced restenosis and (taxol) Go Clear Save Search

Limits Preview/Index History Clipboard Details

Display Summary Show 20 Sort by Send to

All: 52 Review: 13

About Entrez
NCBI ToolBar

Text Version

Items 41 - 52 of 52


Previous Page 3 of 3

Entrez PubMed
Overview
Help | FAQ
Tutorials
New/Noteworthy
E-Utilities


PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI

Related Resources
Order Documents
NLM Mobile
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central


41: Nguyen KT, Su SH, Sheng A, Wawro D, Schwade ND, Brouse CF, Greulich PE, Tang L, Eberhart RC. Related Articles, Links

 In vitro hemocompatibility studies of drug-loaded poly-(L-lactic acid) fibers. Biomaterials. 2003 Dec;24(28):5191-201. PMID: 14568436 [PubMed - indexed for MEDLINE]


42: Scheller B, Speck U, Schmitt A, Bohm M, Nickenig G. Related Articles, Links

 Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coll Cardiol. 2003 Oct 15;42(8):1415-20. PMID: 14563585 [PubMed - indexed for MEDLINE]


43: Garces K. Related Articles, Links

 Drug eluting stents: managing coronary artery stenosis following PTCA. Issues Emerg Health Technol. 2002 Oct;(40):1-6. PMID: 12385349 [PubMed - indexed for MEDLINE]


44: Swanson N, Javed Q, Hogrefe K, Gershlick A. Related Articles, Links

 Human internal mammary artery organ culture model of coronary stenting: a novel investigation of smooth muscle cell response to drug-eluting stents. Clin Sci (Lond). 2002 Oct;103(4):347-53. PMID: 12241533 [PubMed - indexed for MEDLINE]


45: Kolodgie FD, John M, Khurana C, Farb A, Wilson PS, Acampado E, Desai N, Soon-Shiong P, Virmani R. Related Articles, Links

 Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel. Circulation. 2002 Sep 3;106(10):1195-8. PMID: 12208792 [PubMed - indexed for MEDLINE]


46: Yasuda S, Noguchi T, Gohda M, Arai T, Tsutsui N, Nakayama Y, Matsuda T, Nonogi H. Related Articles, Links

 Local delivery of low-dose docetaxel, a novel microtubule polymerizing agent, reduces neointimal hyperplasia in a balloon-injured rabbit iliac artery model. Cardiovasc Res. 2002 Feb 1;53(2):481-6. PMID: 11827699 [PubMed - indexed for MEDLINE]

47: Hong MK, Kornowski R, Bramwell O, Ragheb AO, Leon MB. Related Articles, Links

 Paclitaxel-coated Gianturco-Roubin II (GR II) stents reduce neointimal hyperplasia in a porcine coronary in-stent restenosis model. Coron Artery Dis. 2001 Sep;12(6):513-5. PMID: 11696691 [PubMed - indexed for MEDLINE]

48: Farb A, Heller PF, Shroff S, Cheng L, Kolodgie FD, Carter AJ, Scott DS, Froehlich J, Virmani R. Related Articles, Links

 Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation. 2001 Jul 24;104(4):473-9. PMID: 11468212 [PubMed - indexed for MEDLINE]

☐ 49: [Herdeg C, Oberhoff M, Siegel-Axel DI, Baumbach A, Blattner A, Kuttner A, Schroder S, Karsch KR.](#) Related Articles, Links



[Paclitaxel: a chemotherapeutic agent for prevention of restenosis? Experimental studies in vitro and in vivo]

Z Kardiol. 2000 May;89(5):390-7. German.

PMID: 10900668 [PubMed - indexed for MEDLINE]

☐ 50: [Herdeg C, Oberhoff M, Baumbach A, Blattner A, Axel DI, Schroder S, Heinle H, Karsch KR.](#) Related Articles, Links



Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo.

J Am Coll Cardiol. 2000 Jun;35(7):1969-76.

PMID: 10841250 [PubMed - indexed for MEDLINE]

☐ 51: [Herdeg C, Oberhoff M, Karsch KR.](#) Related Articles, Links



Antiproliferative stent coatings: Taxol and related compounds.

Semin Interv Cardiol. 1998 Sep-Dec;3(3-4):197-9. Review.

PMID: 10406693 [PubMed - indexed for MEDLINE]

had date

☐ 52: [Axel DI, Kunert W, Goggelmann C, Oberhoff M, Herdeg C, Kuttner A, Wild DH, Brehm BR, Riessen R, Koveker G, Karsch KR.](#) Related Articles, Links



Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery.

Circulation. 1997 Jul 15;96(2):636-45.

PMID: 9244237 [PubMed - indexed for MEDLINE]

Items 41 - 52 of 52

Previous

Page

3

of 3

Display

Summary

Show

20

Sort by

Send to

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jan 19 2006 04:31:52

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1653HXP

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	DEC 05	CASREACT(R) - Over 10 million reactions available
NEWS	4	DEC 14	2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS	5	DEC 14	2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS	6	DEC 14	CA/Caplus to be enhanced with updated IPC codes
NEWS	7	DEC 21	IPC search and display fields enhanced in CA/Caplus with the IPC reform
NEWS	8	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/USPAT2
NEWS	9	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS	10	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS	11	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS	12	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS	13	JAN 30	Saved answer limit increased
NEWS	14	JAN 31	Monthly current-awareness alert (SDI) frequency added to TULSA
NEWS	15	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS	16	FEB 22	Status of current WO (PCT) information on STN
NEWS	17	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS	18	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS	19	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	20	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS	21	FEB 28	TOXCENTER reloaded with enhancements
NEWS	22	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS	23	MAR 01	INSPEC reloaded and enhanced
NEWS	24	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS	25	MAR 08	X.25 communication option no longer available after June 2006
NEWS EXPRESS			FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:30:29 ON 09 MAR 2006

=> file medline, uspatful, dgene, embase, wpids, biosis		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 17:30:45 ON 09 MAR 2006

FILE 'USPATFULL' ENTERED AT 17:30:45 ON 09 MAR 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 17:30:45 ON 09 MAR 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'EMBASE' ENTERED AT 17:30:45 ON 09 MAR 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'WPIDS' ENTERED AT 17:30:45 ON 09 MAR 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'BIOSIS' ENTERED AT 17:30:45 ON 09 MAR 2006
Copyright (c) 2006 The Thomson Corporation

=> s restenosis
L1 162469 RESTENOSIS

=> s l1 and reduction or inhibition
L2 1862352 L1 AND REDUCTION OR INHIBITION

=> s (reduce restenosis)
L3 1295 (REDUCE RESTENOSIS)

=> s l3 and l2
L4 630 L3 AND L2

=> s l4 and (following vascular surgery)
L5 8 L4 AND (FOLLOWING VASCULAR SURGERY)

=> d l5 ti abs ibib tot

L5 ANSWER 1 OF 8 USPATFULL on STN
TI Therapeutic inhibitor of vascular smooth muscle cells
AB Methods are provided for inhibiting stenosis or **restenosis** following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:289199 USPATFULL

TITLE: Therapeutic inhibitor of vascular smooth muscle cells
INVENTOR(S): Kunz, Lawrence L., Redmond, WA, UNITED STATES
Klein, Richard A., Edmonds, WA, UNITED STATES
Reno, John M., Brier, WA, UNITED STATES
PATENT ASSIGNEE(S): NeoRx Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003203958	A1	20031030
	US 6720350	B2	20040413
APPLICATION INFO.:	US 2002-330834	A1	20021227 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-24885, filed on 18 Dec 2001, PENDING Continuation of Ser. No. US 1999-361194, filed on 26 Jul 1999, GRANTED, Pat. No. US 6358989 Division of Ser. No. US 1997-829685, filed on 31 Mar 1997, GRANTED, Pat. No. US 5981568		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A., P.O. BOX 2938, MINNEAPOLIS, MN, 55402		
NUMBER OF CLAIMS:	130		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	22 Drawing Page(s)		
LINE COUNT:	5208		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L5 ANSWER 2 OF 8 USPATFULL on STN

TI Therapeutic inhibitor of vascular smooth muscle cells
AB Methods are provided for inhibiting stenosis or **restenosis** following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:57111 USPATFULL
TITLE: Therapeutic inhibitor of vascular smooth muscle cells
INVENTOR(S): Kunz, Lawrence L., Redmond, WA, UNITED STATES
Reno, John M., Brier, WA, UNITED STATES
PATENT ASSIGNEE(S): Angiotech Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003039675	A1	20030227
	US 6569441	B2	20030527
APPLICATION INFO.:	US 2001-995490	A1	20011127 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-896208, filed on 29 Jun 2001, PENDING Division of Ser. No. US 1997-829991, filed on 31 Mar 1997, GRANTED, Pat. No. US 6306421 Continuation-in-part of Ser. No. US 1995-450793, filed on 25 May 1995, GRANTED, Pat. No. US 5811447 Continuation of Ser. No. US 1993-62451, filed on 13 May 1993, ABANDONED Continuation of Ser. No. WO 1996-US2125, filed on 15 Feb 1996, UNKNOWN Continuation-in-part of Ser. No. US 1995-389712, filed on 15 Feb 1995, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A., P.O. BOX		

2938, MINNEAPOLIS, MN, 55402

NUMBER OF CLAIMS: 60
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 21 Drawing Page(s)
LINE COUNT: 5071
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 8 USPATFULL on STN

TI Therapeutic inhibitor of vascular smooth muscle cells
AB Methods are provided for inhibiting stenosis or **restenosis** following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:165265 USPATFULL
TITLE: Therapeutic inhibitor of vascular smooth muscle cells
INVENTOR(S): Kunz, Lawrence L., Redmond, WA, UNITED STATES
Klein, Richard A., Edmonds, WA, UNITED STATES
Reno, John M., Brier, WA, UNITED STATES
PATENT ASSIGNEE(S): NeoRx Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002086896	A1	20020704
	US 6663881	B2	20031216
APPLICATION INFO.:	US 2001-24885	A1	20011218 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-62451, filed on 13 May 1993, ABANDONED Continuation of Ser. No. US 1999-361194, filed on 26 Jul 1999, PATENTED Division of Ser. No. US 1997-829685, filed on 31 Mar 1997, PATENTED Continuation-in-part of Ser. No. US 1995-450793, filed on 25 May 1995, PATENTED Continuation of Ser. No. US 1993-62451, filed on 13 May 1993, ABANDONED Continuation-in-part of Ser. No. US 1993-11669, filed on 28 Jan 1993, ABANDONED Continuation-in-part of Ser. No. WO 1996-US2125, filed on 15 Feb 1996, UNKNOWN Continuation-in-part of Ser. No. US 1995-389712, filed on 15 Feb 1995, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A., P.O. BOX 2938, MINNEAPOLIS, MN, 55402		
NUMBER OF CLAIMS:	90		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	22 Drawing Page(s)		
LINE COUNT:	5092		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 8 USPATFULL on STN

TI Therapeutic inhibitor of vascular smooth muscle cells
AB Methods are provided for inhibiting stenosis or **restenosis** following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are

pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:57821 USPATFULL
TITLE: Therapeutic inhibitor of vascular smooth muscle cells
INVENTOR(S): Kunz, Lawrence L., Redmond, WA, United States
Klein, Richard A., Edmonds, WA, United States
Reno, John M., Brier, WA, United States
PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6358989	B1	20020319
APPLICATION INFO.:	US 1999-361194		19990726 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-829685, filed on 31 Mar 1997 Continuation-in-part of Ser. No. US 1995-450793, filed on 25 May 1995, now patented, Pat. No. US 5811447 Continuation of Ser. No. WO 1996-US2125, filed on 15 Feb 1996 Continuation-in-part of Ser. No. US 1995-389712, filed on 15 Feb 1995 Continuation of Ser. No. US 1993-62451, filed on 13 May 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Barts, Samuel		
LEGAL REPRESENTATIVE:	Schwegman, Lundenberg, Woessner & Kluth, PA		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	30 Drawing Figure(s); 22 Drawing Page(s)		
LINE COUNT:	5403		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 8 USPATFULL on STN

TI Therapeutic inhibitor of vascular smooth muscle cells
AB Methods are provided for inhibiting stenosis or **restenosis** following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:43612 USPATFULL
TITLE: Therapeutic inhibitor of vascular smooth muscle cells
INVENTOR(S): Kunz, Lawrence L., Redmond, WA, UNITED STATES
Reno, John M., Brier, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002025979	A1	20020228
	US 6491938	B2	20021210
APPLICATION INFO.:	US 2001-896208	A1	20010629 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-829991, filed on 31 Mar 1997, PENDING Continuation-in-part of Ser. No. US 1995-450793, filed on 25 May 1995, GRANTED, Pat. No. US 5811447 Continuation of Ser. No. US 1993-62451, filed on 13 May 1993, ABANDONED Continuation of Ser. No. WO 1996-US2125, filed on 15 Feb 1996, UNKNOWN Continuation-in-part of Ser. No. US 1995-389712, filed		

on 15 Feb 1995, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A., 1600 TCF
TOWER, 121 SOUTH 8TH STREET, MINNEAPOLIS, MN, 55402
NUMBER OF CLAIMS: 60
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Page(s)
LINE COUNT: 5068
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 8 USPATFULL on STN

TI Therapeutic inhibitor of vascular smooth muscle cells
AB Methods are provided for inhibiting stenosis or **restenosis**
following vascular trauma in a mammalian host, comprising administering
to the host a therapeutically effective dosage of a cytostatic agent
and/or cytoskeletal inhibitor so as to biologically stent the
traumatized vessel. Also provided is a method to inhibit or reduce
vascular remodeling following vascular trauma, comprising administering
an effective amount of a cytoskeletal inhibitor. Further provided are
pharmaceutical compositions and kits comprising the therapeutic agents
of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:184866 USPATFULL
TITLE: Therapeutic inhibitor of vascular smooth muscle cells
INVENTOR(S): Kunz, Lawrence L., Redmond, WA, United States
Reno, John M., Brier, WA, United States
PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6306421	B1	20011023
APPLICATION INFO.:	US 1997-829991		19970331 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-450793, filed on 25 May 1995, now patented, Pat. No. US 5811447 Continuation of Ser. No. US 1993-62451, filed on 13 May 1993, now abandoned Continuation-in-part of Ser. No. US 1993-11669, filed on 28 Jan 1993 Continuation-in-part of Ser. No. WO 1992-US8220, filed on 25 Sep 1992 Continuation-in-part of Ser. No. WO 1996-US2125, filed on 15 Feb 1996 Continuation-in-part of Ser. No. US 1995-389712, filed on 15 Feb 1995, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Barts, Samuel
LEGAL REPRESENTATIVE: Schwegman, Lundberg, Woessner & Kluth, P.A.
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 30 Drawing Figure(s); 22 Drawing Page(s)
LINE COUNT: 5649
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 8 USPATFULL on STN

TI Therapeutic inhibitor of vascular smooth muscle cells
AB Methods are provided for inhibiting stenosis following vascular trauma
or disease in a mammalian host, comprising administering to the host a
therapeutically effective dosage of a therapeutic conjugate containing a
vascular smooth muscle binding protein that associates in a specific
manner with a cell surface of the vascular smooth muscle cell, coupled
to a therapeutic agent dosage form that inhibits a cellular activity of
the muscle cell. Methods are also provided for the direct and/or

targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:4284 USPATFULL
TITLE: Therapeutic inhibitor of vascular smooth muscle cells
INVENTOR(S): Kunz, Lawrence L., Redmond, WA, United States
PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6171609	B1	20010109
APPLICATION INFO.:	US 1995-546794		19951023 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-389712, filed on 15 Feb 1995		
DOCUMENT TYPE:	Patent		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Barts, Samuel		
LEGAL REPRESENTATIVE:	Schwegman, Lundberg, Woessner & Kluth P.A.		
NUMBER OF CLAIMS:	73		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	27 Drawing Figure(s); 19 Drawing Page(s)		
LINE COUNT:	4091		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 8 USPATFULL on STN

TI Therapeutic inhibitor of vascular smooth muscle cells
AB Methods are provided for inhibiting stenosis or **restenosis** following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:141975 USPATFULL
TITLE: Therapeutic inhibitor of vascular smooth muscle cells
INVENTOR(S): Kunz, Lawrence L., Redmond, WA, United States
Klein, Richard A., Edmonds, WA, United States
Reno, John M., Brier, WA, United States
PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5981568		19991109
APPLICATION INFO.:	US 1997-829685		19970331 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-450793, filed on 25 May 1995, now patented, Pat. No. US 5811447 which is a continuation of Ser. No. US 1993-62451, filed on 13 May 1993, now abandoned And a continuation-in-part of Ser. No. WO 1996-US2125, filed on 15 Feb 1996 which is a continuation-in-part of Ser. No. US 1995-389712, filed on 15 Feb 1995		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Barts, Samuel		
LEGAL REPRESENTATIVE:	Schwegman, Lundberg, Woessner & Kluth, P.A.		

NUMBER OF CLAIMS: 56
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 30 Drawing Figure(s); 22 Drawing Page(s)
LINE COUNT: 5553
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 17:30:29 ON 09 MAR 2006)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, BIOSIS' ENTERED AT
17:30:45 ON 09 MAR 2006

L1 162469 S RESTENOSIS
L2 1862352 S L1 AND REDUCTION OR INHIBITION
L3 1295 S (REDUCE RESTENOSIS)
L4 630 S L3 AND L2
L5 8 S L4 AND (FOLLOWING VASCULAR SURGERY)

=> s l4 and (non-biodegradable)

L6 42 L4 AND (NON-BIODEGRADABLE)

=> s l6 and (sustained release dosage form)

L7 11 L6 AND (SUSTAINED RELEASE DOSAGE FORM)

=> d l7 ti abs ibib tot

L7 ANSWER 1 OF 11 USPATFULL on STN

TI Coated stent with protective packaging and method of using same
AB A coated stent with protective packaging is provided. The coated stent
comprises at least one stent segment and a tray including a stent void
disposed therein, wherein the stent segment is restricted from movement
with respect to the tray while disposed within the stent void. Systems
and method for the coated stent are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:308535 USPATFULL
TITLE: Coated stent with protective packaging and method of
using same
INVENTOR(S): Farrell, Thomas, Galway, IRELAND
Quinn, Colm, Longford, IRELAND
PATENT ASSIGNEE(S): Medtronic Vascular, Inc., Santa Rosa, CA (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004243214	A1	20041202
APPLICATION INFO.:	US 2004-827982	A1	20040420 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-464865P	20030423 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FRANK C. NICHOLAS, CARDINAL LAW GROUP, Suite 2000, 1603 Orrington Avenue, Evanston, IL, 60201	

NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 710
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 2 OF 11 USPATFULL on STN

TI Therapeutic inhibitor of vascular smooth muscle cells
AB Methods are provided for inhibiting stenosis or **restenosis** following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:289199 USPATFULL
TITLE: Therapeutic inhibitor of vascular smooth muscle cells
INVENTOR(S): Kunz, Lawrence L., Redmond, WA, UNITED STATES
Klein, Richard A., Edmonds, WA, UNITED STATES
Reno, John M., Brier, WA, UNITED STATES
PATENT ASSIGNEE(S): NeoRx Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003203958	A1	20031030
	US 6720350	B2	20040413
APPLICATION INFO.:	US 2002-330834	A1	20021227 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-24885, filed on 18 Dec 2001, PENDING Continuation of Ser. No. US 1999-361194, filed on 26 Jul 1999, GRANTED, Pat. No. US 6358989 Division of Ser. No. US 1997-829685, filed on 31 Mar 1997, GRANTED, Pat. No. US 5981568		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A., P.O. BOX 2938, MINNEAPOLIS, MN, 55402		
NUMBER OF CLAIMS:	130		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	22 Drawing Page(s)		
LINE COUNT:	5208		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 11 USPATFULL on STN

TI Coated stent with protective assembly and method of using same
AB A stent with a protective assembly is provided. The stent comprises at least one stent segment, operatively adapted for deployment from the sheath member, and at least one sheath member removably enclosing the stent segment and operatively adapted to protect the stent segment from handling. Methods and systems for use of the stent are also provided.

ACCESSION NUMBER: 2003:266475 USPATFULL
TITLE: Coated stent with protective assembly and method of using same
INVENTOR(S): Campbell, Todd, Petaluma, CA, UNITED STATES
Cervantes, Marvin, Santa Rosa, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003187493	A1	20031002
APPLICATION INFO.:	US 2002-112146	A1	20020329 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MEDTRONIC AVE, INC., 3576 UNOCAL PLACE, SANTA ROSA, CA, 95403		
NUMBER OF CLAIMS:	44		
EXEMPLARY CLAIM:	1		

NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 809

L7 ANSWER 4 OF 11 USPATFULL on STN

TI Therapeutic inhibitor of vascular smooth muscle cells

AB Methods are provided for inhibiting stenosis or **restenosis** following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:57111 USPATFULL

TITLE: Therapeutic inhibitor of vascular smooth muscle cells

INVENTOR(S): Kunz, Lawrence L., Redmond, WA, UNITED STATES

Reno, John M., Brier, WA, UNITED STATES

PATENT ASSIGNEE(S): Angiotech Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003039675	A1	20030227
	US 6569441	B2	20030527
APPLICATION INFO.:	US 2001-995490	A1	20011127 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-896208, filed on 29 Jun 2001, PENDING Division of Ser. No. US 1997-829991, filed on 31 Mar 1997, GRANTED, Pat. No. US 6306421		
	Continuation-in-part of Ser. No. US 1995-450793, filed on 25 May 1995, GRANTED, Pat. No. US 5811447		
	Continuation of Ser. No. US 1993-62451, filed on 13 May 1993, ABANDONED Continuation of Ser. No. WO 1996-US2125, filed on 15 Feb 1996, UNKNOWN		
	Continuation-in-part of Ser. No. US 1995-389712, filed on 15 Feb 1995, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A., P.O. BOX 2938, MINNEAPOLIS, MN, 55402		
NUMBER OF CLAIMS:	60		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	21 Drawing Page(s)		
LINE COUNT:	5071		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 11 USPATFULL on STN

TI Therapeutic inhibitor of vascular smooth muscle cells

AB Methods are provided for inhibiting stenosis or **restenosis** following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:165265 USPATFULL

TITLE: Therapeutic inhibitor of vascular smooth muscle cells

INVENTOR(S): Kunz, Lawrence L., Redmond, WA, UNITED STATES

PATENT ASSIGNEE(S): Klein, Richard A., Edmonds, WA, UNITED STATES
Reno, John M., Brier, WA, UNITED STATES
NeoRx Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002086896	A1	20020704
	US 6663881	B2	20031216
APPLICATION INFO.:	US 2001-24885	A1	20011218 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-62451, filed on 13 May 1993, ABANDONED Continuation of Ser. No. US 1999-361194, filed on 26 Jul 1999, PATENTED Division of Ser. No. US 1997-829685, filed on 31 Mar 1997, PATENTED Continuation-in-part of Ser. No. US 1995-450793, filed on 25 May 1995, PATENTED Continuation of Ser. No. US 1993-62451, filed on 13 May 1993, ABANDONED Continuation-in-part of Ser. No. US 1993-11669, filed on 28 Jan 1993, ABANDONED Continuation-in-part of Ser. No. WO 1996-US2125, filed on 15 Feb 1996, UNKNOWN Continuation-in-part of Ser. No. US 1995-389712, filed on 15 Feb 1995, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A., P.O. BOX 2938, MINNEAPOLIS, MN, 55402		
NUMBER OF CLAIMS:	90		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	22 Drawing Page(s)		
LINE COUNT:	5092		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L7 ANSWER 6 OF 11 USPATFULL on STM
TI Therapeutic inhibitor of vascular smooth muscle cells
AB Methods are provided for inhibiting stenosis or **restenosis** following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:57821 USPATFULL
TITLE: Therapeutic inhibitor of vascular smooth muscle cells
INVENTOR(S): Kunz, Lawrence L., Redmond, WA, United States
Klein, Richard A., Edmonds, WA, United States
Reno, John M., Brier, WA, United States
PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6358989	B1	20020319
APPLICATION INFO.:	US 1999-361194		19990726 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-829685, filed on 31 Mar 1997 Continuation-in-part of Ser. No. US 1995-450793, filed on 25 May 1995, now patented, Pat. No. US 5811447 Continuation of Ser. No. WO 1996-US2125, filed on 15 Feb 1996 Continuation-in-part of Ser. No. US 1995-389712, filed on 15 Feb 1995 Continuation of Ser. No. US 1993-62451, filed on 13 May 1993, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Barts, Samuel
LEGAL REPRESENTATIVE: Schwegman, Lundenberg, Woessner & Kluth, PA
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 30 Drawing Figure(s); 22 Drawing Page(s)
LINE COUNT: 5403
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 7 OF 11 USPATFULL on STN

TI Therapeutic inhibitor of vascular smooth muscle cells

AB Methods are provided for inhibiting stenosis or **restenosis** following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:43612 USPATFULL
TITLE: Therapeutic inhibitor of vascular smooth muscle cells
INVENTOR(S): Kunz, Lawrence L., Redmond, WA, UNITED STATES
Reno, John M., Brier, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002025979	A1	20020228
	US 6491938	B2	20021210
APPLICATION INFO.:	US 2001-896208	A1	20010629 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-829991, filed on 31 Mar 1997, PENDING Continuation-in-part of Ser. No. US 1995-450793, filed on 25 May 1995, GRANTED, Pat. No. US 5811447 Continuation of Ser. No. US 1993-62451, filed on 13 May 1993, ABANDONED Continuation of Ser. No. WO 1996-US2125, filed on 15 Feb 1996, UNKNOWN Continuation-in-part of Ser. No. US 1995-389712, filed on 15 Feb 1995, PENDING		

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A., 1600 TCF TOWER, 121 SOUTH 8TH STREET, MINNEAPOLIS, MN, 55402
NUMBER OF CLAIMS: 60
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Page(s)
LINE COUNT: 5068
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 8 OF 11 USPATFULL on STN

TI Therapeutic inhibitor of vascular smooth muscle cells

AB Methods are provided for inhibiting stenosis or **restenosis** following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:184866 USPATFULL
TITLE: Therapeutic inhibitor of vascular smooth muscle cells
INVENTOR(S): Kunz, Lawrence L., Redmond, WA, United States
Reno, John M., Brier, WA, United States
PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6306421	B1	20011023
APPLICATION INFO.:	US 1997-829991		19970331 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-450793, filed on 25 May 1995, now patented, Pat. No. US 5811447 Continuation of Ser. No. US 1993-62451, filed on 13 May 1993, now abandoned Continuation-in-part of Ser. No. US 1993-11669, filed on 28 Jan 1993 Continuation-in-part of Ser. No. WO 1992-US8220, filed on 25 Sep 1992 Continuation-in-part of Ser. No. WO 1996-US2125, filed on 15 Feb 1996 Continuation-in-part of Ser. No. US 1995-389712, filed on 15 Feb 1995, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Barts, Samuel		
LEGAL REPRESENTATIVE:	Schwegman, Lundberg, Woessner & Kluth, P.A.		
NUMBER OF CLAIMS:	36		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	30 Drawing Figure(s); 22 Drawing Page(s)		
LINE COUNT:	5649		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 9 OF 11 USPATFULL on STN

TI Prevention and treatment of cardiovascular pathologies with tamoxifen analogues

AB A method for treating or preventing cardiovascular pathologies by administering a compound of the formula (I): ##STR1##

wherein Z is C.dbd.O or a covalent bond; Y is H or O(C.sub.1 -C.sub.4)alkyl, R.sup.1 and R.sup.2 are individually (C.sub.1 -C.sub.4)alkyl or together with N are a saturated heterocyclic group, R.sup.3 is ethyl or chloroethyl, R.sup.4 is H, R.sup.5 is I, O(C.sub.1 -C.sub.4)alkyl or H and R.sup.6 is I, O(C.sub.1 -C.sub.4)alkyl or H with the proviso that when R.sup.4, R.sup.5, and R.sup.6 are H, R.sup.3 is not ethyl; or a pharmaceutically acceptable salt thereof, effective to elevate the level of TGF-beta to treat and/or prevent conditions such as atherosclerosis, thrombosis, myocardial infarction, and stroke is provided. Useful compounds include idoxifene, toremifene or salts thereof. Further provided is a method for identifying an agent that elevates the level of TGF-beta. Another embodiment of the invention is an assay or kit to determine TGF-beta in vitro. Also provided is a therapeutic method comprising inhibiting smooth muscle cell proliferation associated with procedural vascular trauma employing the administration of tamoxifen or structural analogs thereof, including compounds of formula (I).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:33286 USPATFULL
TITLE: Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
INVENTOR(S): Grainger, David J., Cambridge, United Kingdom
Metcalfe, James C., Cambridge, United Kingdom
Kunz, Lawrence L., Redmond, WA, United States
Schroff, Robert W., Edmonds, WA, United States

PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6197789	B1	20010306
	WO 9640098		19961219
APPLICATION INFO.:	US 1997-973570		19971205 (8)
	WO 1996-US10211		19960607
			19980908 PCT 371 date
			19980908 PCT 102(e) date
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-478936, filed on 7 Jun 1995, now abandoned Continuation-in-part of Ser. No. US 1995-476735, filed on 7 Jun 1995, now patented, Pat. No. US 5595722 Continuation-in-part of Ser. No. US 1995-477393, filed on 7 Jun 1995 Continuation-in-part of Ser. No. US 1995-486334, filed on 7 Jun 1995, now patented, Pat. No. US 5770609		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Criares, Theodore J.		
LEGAL REPRESENTATIVE:	Schwegman, Lundberg, Woessner & Kluth, P.A.		
NUMBER OF CLAIMS:	17		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 5 Drawing Page(s)		
LINE COUNT:	4577		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L7 ANSWER 10 OF 11 USPATFULL on STN

TI Therapeutic inhibitor of vascular smooth muscle cells

AB Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:4284 USPATFULL
TITLE: Therapeutic inhibitor of vascular smooth muscle cells
INVENTOR(S): Kunz, Lawrence L., Redmond, WA, United States
PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6171609	B1	20010109
APPLICATION INFO.:	US 1995-546794		19951023 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-389712, filed on 15 Feb 1995		
DOCUMENT TYPE:	Patent		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Barts, Samuel		
LEGAL REPRESENTATIVE:	Schwegman, Lundberg, Woessner & Kluth P.A.		
NUMBER OF CLAIMS:	73		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	27 Drawing Figure(s); 19 Drawing Page(s)		
LINE COUNT:	4091		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L7 ANSWER 11 OF 11 USPATFULL on STN

TI Therapeutic inhibitor of vascular smooth muscle cells

AB Methods are provided for inhibiting stenosis or **restenosis** following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:141975 USPATFULL

TITLE: Therapeutic inhibitor of vascular smooth muscle cells

INVENTOR(S): Kunz, Lawrence L., Redmond, WA, United States

Klein, Richard A., Edmonds, WA, United States

Reno, John M., Brier, WA, United States

PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5981568		19991109
APPLICATION INFO.:	US 1997-829685		19970331 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-450793, filed on 25 May 1995, now patented, Pat. No. US 5811447 which is a continuation of Ser. No. US 1993-62451, filed on 13 May 1993, now abandoned And a continuation-in-part of Ser. No. WO 1996-US2125, filed on 15 Feb 1996 which is a continuation-in-part of Ser. No. US 1995-389712, filed on 15 Feb 1995		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Barts, Samuel		
LEGAL REPRESENTATIVE:	Schwegman, Lundberg, Woessner & Kluth, P.A.		
NUMBER OF CLAIMS:	56		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	30 Drawing Figure(s); 22 Drawing Page(s)		
LINE COUNT:	5553		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> e kunz, 1/au

E1	1	KUNZ YVONNE M/AU
E2	1	KUNZ YW/AU
E3	0 -->	KUNZ, L/AU
E4	1	KUNZA A/AU
E5	1	KUNZACK H/AU
E6	2	KUNZAGK H/AU
E7	5	KUNZE/AU
E8	1	KUNZE 13 05 M/AU
E9	55	KUNZE A/AU
E10	4	KUNZE A G/AU
E11	4	KUNZE A K/AU
E12	1	KUNZE A M/AU

=> d his

(FILE 'HOME' ENTERED AT 17:30:29 ON 09 MAR 2006)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, BIOSIS' ENTERED AT

17:30:45 ON 09 MAR 2006

L1 162469 S RESTENOSIS
L2 1862352 S L1 AND REDUCTION OR INHIBITION
L3 1295 S (REDUCE RESTENOSIS)
L4 630 S L3 AND L2
L5 8 S L4 AND (FOLLOWING VASCULAR SURGERY)
L6 42 S L4 AND (NON-BIODEGRADABLE)
L7 11 S L6 AND (SUSTAINED RELEASE DOSAGE FORM)
E KUNZ, L/AU

=> s smooth muscle cell migration
L8 2597 SMOOTH MUSCLE CELL MIGRATION

=> s 18 and inhibition
L9 1082 L8 AND INHIBITION

=> s 19 and (inhibit proliferation)
L10 31 L9 AND (INHIBIT PROLIFERATION)

=> s 110 and (taxol or taxol analog or taxotere)
L11 12 L10 AND (TAXOL OR TAXOL ANALOG OR TAXOTERE)

=> d 111 ti abs ibib tot

L11 ANSWER 1 OF 12 USPATFULL on STN

TI Therapeutic inhibitor of vascular smooth muscle cells

AB Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:279923 USPATFULL

TITLE: Therapeutic inhibitor of vascular smooth muscle cells

INVENTOR(S): Kunz, Lawrence L., Redmond, WA, UNITED STATES

PATENT ASSIGNEE(S): Scimed Life Systems, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004219223	A1	20041104
APPLICATION INFO.:	US 2004-860486	A1	20040602 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-190211, filed on 3 Jul 2002, ABANDONED Continuation of Ser. No. US 1997-894350, filed on 10 Oct 1997, ABANDONED A 371 of International Ser. No. WO 1996-US2125, filed on 15 Feb 1996, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017		
NUMBER OF CLAIMS:	32		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	20 Drawing Page(s)		
LINE COUNT:	3811		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 2 OF 12 USPATFULL on STN

TI Use of biomolecular targets in the treatment and visualization of brain

tumors

AB The present invention relates to the use of proteins that are differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as biomolecular targets for brain tumor treatment therapies. Specifically, the present invention relates to the use of therapeutic and imaging agents, which specifically bind to one or more of the identified brain tumor protein targets. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention. Nucleic acid probes specific for the spliced mRNA encoding these variants and affinity reagents specific for the novel proteins are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:1822 USPATFULL
TITLE: Use of biomolecular targets in the treatment and visualization of brain tumors
INVENTOR(S): Nagavarapu, Usha, San Jose, CA, UNITED STATES
Shivak, David A., San Mateo, CA, UNITED STATES
Chin, Daniel J., Foster City, CA, UNITED STATES
Foehr, Erik D., Novato, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004001841	A1	20040101
APPLICATION INFO.:	US 2003-407365	A1	20030403 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-369743P	20020403 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOZICEVIC, FIELD & FRANCIS LLP, 200 MIDDLEFIELD RD, SUITE 200, MENLO PARK, CA, 94025	
NUMBER OF CLAIMS:	49	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	4185	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 3 OF 12 USPATFULL on STN

TI Compositions and methods for treatment of hyperplasia
AB In accordance with the present invention, there are provided methods for treating hyperplasia in a subject in need thereof. In another aspect of the invention, there are provided methods for reducing neointimal hyperplasia associated with vascular interventional procedures. Formulations contemplated for use herein comprise proteins and at least one pharmaceutically active agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:283081 USPATFULL
TITLE: Compositions and methods for treatment of hyperplasia
INVENTOR(S): Desai, Neil P., Los Angeles, CA, UNITED STATES
Soon-Shiong, Patrick, Los Angeles, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199425	A1	20031023
APPLICATION INFO.:	US 2001-847945	A1	20010502 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-446783, filed on 16 May 2000, PENDING		

NUMBER	DATE
-----	-----

PRIORITY INFORMATION: WO 1998-US13272 19980626
US 1997-51021P 19970627 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY & LARDNER, P.O. BOX 80278, SAN DIEGO, CA,
92138-0278
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 1243
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 4 OF 12 USPATFULL on STN

TI Therapeutic inhibitor of vascular smooth muscle cells
AB Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:121249 USPATFULL
TITLE: Therapeutic inhibitor of vascular smooth muscle cells
INVENTOR(S): Kunz, Lawrence L., Redmond, WA, UNITED STATES
PATENT ASSIGNEE(S): NeoRx Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003083733	A1	20030501
APPLICATION INFO.:	US 2002-190211	A1	20020703 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-894350, filed on 10 Oct 1997, ABANDONED A 371 of International Ser. No. WO 1996-US2125, filed on 15 Feb 1996, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A., P.O. BOX 2938, MINNEAPOLIS, MN, 55402		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	20 Drawing Page(s)		
LINE COUNT:	3787		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 5 OF 12 USPATFULL on STN

TI Therapeutic inhibitor of vascular smooth muscle cells
AB Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:33501 USPATFULL

TITLE: Therapeutic inhibitor of vascular smooth muscle cells
INVENTOR(S): Kunz, Lawrence L., Redmond, WA, United States
Klein, Richard A., Lynnwood, WA, United States
PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6515009	B1	20030204
APPLICATION INFO.:	US 1995-389712		19950215 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-450793, filed on 25 May 1995 Continuation of Ser. No. US 1993-62451, filed on 13 May 1993 Continuation-in-part of Ser. No. US 1993-11669, filed on 28 Jan 1993, now abandoned Continuation-in-part of Ser. No. WO 1992-US8220, filed on 25 Sep 1992 Continuation-in-part of Ser. No. US 1991-767254, filed on 27 Sep 1991		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Barts, Samuel		
LEGAL REPRESENTATIVE:	Schwegman, Lundberg, Woessner & Kluth, P.A.		
NUMBER OF CLAIMS:	72		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	27 Drawing Figure(s); 19 Drawing Page(s)		
LINE COUNT:	4378		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L11 ANSWER 6 OF 12 USPATFULL on STN

TI Therapeutic inhibitor of vascular smooth muscle cells
AB Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:72924 USPATFULL
TITLE: Therapeutic inhibitor of vascular smooth muscle cells
INVENTOR(S): Kunz, Lawrence L., Redmond, WA, UNITED STATES
Klein, Richard A., Lynnwood, WA, UNITED STATES
PATENT ASSIGNEE(S): NeoRx Corporation. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002040064	A1	20020404
	US 6599928	B2	20030729
APPLICATION INFO.:	US 2001-910387	A1	20010720 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-389712, filed on 15 Feb 1995, PENDING Continuation-in-part of Ser. No. US 1993-11669, filed on 28 Jan 1993, ABANDONED Continuation-in-part of Ser. No. WO 1992-US8220, filed on 25 Sep 1992, UNKNOWN		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A., P.O. BOX 2938, MINNEAPOLIS, MN, 55402		
NUMBER OF CLAIMS:	25		
EXEMPLARY CLAIM:	1		

NUMBER OF DRAWINGS: 19 Drawing Page(s)
LINE COUNT: 3758
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 7 OF 12 USPATFULL on STN

TI Therapeutic inhibitor of vascular smooth muscle cells
AB Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent. Also discussed are mechanisms for in vivo vascular smooth muscle cell proliferation modulation, agents that impact those mechanisms and protocols for the use of those agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:22439 USPATFULL
TITLE: Therapeutic inhibitor of vascular smooth muscle cells
INVENTOR(S): Kunz, Lawrence L., Redmond, WA, UNITED STATES
Klein, Richard A., Lynnwood, WA, UNITED STATES
Reno, John M., Brier, WA, UNITED STATES
Grainger, David J., Cambridge, UNITED KINGDOM
Metcalfe, James C., Cambridge, UNITED KINGDOM
Weissberg, Peter L., Cambridge, UNITED KINGDOM
Anderson, Peter G., Birmingham, AL, UNITED STATES
PATENT ASSIGNEE(S): NeoRx Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002013275	A1	20020131
APPLICATION INFO.:	US 2001-910388	A1	20010720 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-470662, filed on 22 Dec 1999, GRANTED, Pat. No. US 6268390 Continuation of Ser. No. US 1998-113733, filed on 10 Jul 1998, GRANTED, Pat. No. US 6074659 Continuation of Ser. No. US 1995-450793, filed on 25 May 1995, GRANTED, Pat. No. US 5811447 Continuation of Ser. No. US 1993-62451, filed on 13 May 1993, ABANDONED Continuation-in-part of Ser. No. US 1993-11669, filed on 28 Jan 1993, ABANDONED Continuation-in-part of Ser. No. WO 1992-US8220, filed on 25 Sep 1992, UNKNOWN		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.O. BOX 2938, MINNEAPOLIS, MN, 55402		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	21 Drawing Page(s)		
LINE COUNT:	4431		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 8 OF 12 USPATFULL on STN

TI Therapeutic inhibitor of vascular smooth muscle cells
AB Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled

to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent. Also discussed are mechanisms for in vivo vascular smooth muscle cell proliferation modulation, agents that impact those mechanisms and protocols for the use of those agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:121497 USPATFULL
 TITLE: Therapeutic inhibitor of vascular smooth muscle cells
 INVENTOR(S): Kunz, Lawrence L., Redmond, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6268390	B1	20010731
APPLICATION INFO.:	US 1999-470662		19991222 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-113733, filed on 10 Jul 1998, now patented, Pat. No. US 6074659		
	Continuation of Ser. No. US 1995-450793, filed on 25 May 1995, now patented, Pat. No. US 5811447		
	Continuation of Ser. No. US 1993-62451, filed on 13 May 1993, now abandoned Continuation-in-part of Ser. No. US 1993-11669, filed on 28 Jan 1993, now abandoned		
	Continuation-in-part of Ser. No. WO 1992-US8220, filed on 25 Sep 1992 Continuation-in-part of Ser. No. US 1991-767254, filed on 27 Sep 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Carlson, Karen Cochrane		
ASSISTANT EXAMINER:	Robinson, Patricia		
LEGAL REPRESENTATIVE:	Schwegman, Lundberg, Woessner & Kluth, P.A.		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	29 Drawing Figure(s); 21 Drawing Page(s)		
LINE COUNT:	4342		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 9 OF 12 USPATFULL on STN

TI Therapeutic inhibitor of vascular smooth muscle cells
 AB Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:4284 USPATFULL
 TITLE: Therapeutic inhibitor of vascular smooth muscle cells
 INVENTOR(S): Kunz, Lawrence L., Redmond, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

NUMBER	KIND	DATE
-----	-----	-----

PATENT INFORMATION: US 6171609 B1 20010109
APPLICATION INFO.: US 1995-546794 19951023 (8)
RELATED APPLN. INFO.: Division of Ser. No. US 1995-389712, filed on 15 Feb 1995
DOCUMENT TYPE: Patent
FILE SEGMENT: Granted
PRIMARY EXAMINER: Barts, Samuel
LEGAL REPRESENTATIVE: Schwegman, Lundberg, Woessner & Kluth P.A.
NUMBER OF CLAIMS: 73
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 27 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 4091
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 10 OF 12 USPATFULL on STN

TI Therapeutic inhibitor of vascular smooth muscle cells
AB Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent. Also discussed are mechanisms for in vivo vascular smooth muscle cell proliferation modulation, agents that impact those mechanisms and protocols for the use of those agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:73925 USPATFULL
TITLE: Therapeutic inhibitor of vascular smooth muscle cells
INVENTOR(S): Kunz, Lawrence L., Redmond, WA, United States
Klein, Richard A., Lynnwood, WA, United States
Reno, John M., Brier, WA, United States
Grainger, David J., Cambridge, United Kingdom
Metcalfe, James C., Cambridge, United Kingdom
Weissberg, Peter L., Cambridge, United Kingdom
Anderson, Peter G., Birmingham, AL, United States
PATENT ASSIGNEE(S): NoeRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6074659		20000613
APPLICATION INFO.:	US 1998-113733		19980710 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-450793, filed on 25 May 1995, now patented, Pat. No. US 5811447 which is a continuation of Ser. No. US 1993-62451, filed on 13 May 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-11669, filed on 28 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. WO 1992-US8220, filed on 25 Sep 1992 which is a continuation-in-part of Ser. No. US 1991-767254, filed on 27 Sep 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Barts, Samuel		
LEGAL REPRESENTATIVE:	Schwegman, Lundberg Woessner & Kluth P.A.		
NUMBER OF CLAIMS:	26		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	29 Drawing Figure(s); 21 Drawing Page(s)		

LINE COUNT: 4818
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 11 OF 12 USPATFULL on STN

TI Therapeutic inhibitor of vascular smooth muscle cells
AB Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent. Also discussed are mechanisms for in vivo vascular smooth muscle cell proliferation modulation, agents that impact those mechanisms and protocols for the use of those agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:115762 USPATFULL
TITLE: Therapeutic inhibitor of vascular smooth muscle cells
INVENTOR(S): Kunz, Lawrence L., Redmond, WA, United States
Klein, Richard A., Lynnwood, WA, United States
Reno, John M., Brier, WA, United States
Grainger, David J., Cambridge, England
Metcalf, James C., Cambridge, England
Weissberg, Peter L., Cambridge, England
Anderson, Peter G., Birmingham, AL, United States
PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5811447		19980922
APPLICATION INFO.:	US 4507932		19950525 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. 62451, filed on 13 May 1993, now abandoned which is a continuation-in-part of Ser. No. 11669, filed on 28 Jan 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Barts, Samuel		
LEGAL REPRESENTATIVE:	Schwegman, Lundberg, Woessner & Kluth, P.A.		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	29 Drawing Figure(s); 21 Drawing Page(s)		
LINE COUNT:	4812		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 12 OF 12 USPATFULL on STN

TI Therapeutic inhibitor of vascular smooth muscle cells
AB Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent. Also discussed are mechanisms for in vivo vascular smooth muscle cell proliferation modulation, agents that impact those mechanisms and

protocols for the use of those agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:33947 USPATFULL
TITLE: Therapeutic inhibitor of vascular smooth muscle cells
INVENTOR(S): Kunz, Lawrence L., Redmond, WA, United States
Klein, Richard A., Lynnwood, WA, United States
Reno, John M., Brier, WA, United States
Grainger, David J., Cambridge, United Kingdom
Metcalf, James C., Cambridge, United Kingdom
Weissberg, Peter L., Cambridge, United Kingdom
Anderson, Peter G., Birmingham, AL, United States
PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5733925		19980331
APPLICATION INFO.:	US 1996-738733		19961028 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-450793, filed on 25 May 1995 which is a continuation of Ser. No. US 1993-62451, filed on 13 May 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-11669, filed on 28 Jan 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Barts, Samuel		
LEGAL REPRESENTATIVE:	Schwegman, Lundberg, Woessner & Kluth, P.A.		
NUMBER OF CLAIMS:	28		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	29 Drawing Figure(s); 21 Drawing Page(s)		
LINE COUNT:	4753		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.